Trial Profile
A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IORCVP) versus Gemcitabine plus Rituximab and CVP (GemRCVP) for the first line treatment of patients with diffuse large B cell lymphoma who are not suitable for anthracycline containing chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Gemcitabine; Prednisolone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Lymphoma
- Focus Therapeutic Use
- Acronyms INCA
- 17 May 2022 Status changed from active, no longer recruiting to completed.
- 03 Nov 2020 Planned End Date changed from 1 Sep 2021 to 1 Oct 2021.
- 21 Jun 2020 Results (n=129) presented at the 25th Congress of the European Haematology Association